AUTHOR=Chaudhury Arun , Duvoor Chitharanjan , Reddy Dendi Vijaya Sena , Kraleti Shashank , Chada Aditya , Ravilla Rahul , Marco Asween , Shekhawat Nawal Singh , Montales Maria Theresa , Kuriakose Kevin , Sasapu Appalanaidu , Beebe Alexandria , Patil Naveen , Musham Chaitanya K. , Lohani Govinda Prasad , Mirza Wasique 

TITLE=Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management

JOURNAL=Frontiers in Endocrinology

VOLUME=Volume 8 - 2017

YEAR=2017

URL=https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2017.00006

DOI=10.3389/fendo.2017.00006

ISSN=1664-2392

ABSTRACT=Type 2 diabetes mellitus (T2DM) is a global pandemic, as evident from the global cartographic picture of diabetes by the International Diabetes Federation (http://www.diabetesatlas.org/). Diabetes mellitus (DM) is a chronic, progressive, incompletely understood metabolic condition chiefly characterized by hyperglycemia. Either impaired insulin secretion, resistance to tissue actions of insulin or a combination of both are thought to be the commonest reasons contributing to the pathophysiology of T2DM, a spectrum of disease originally arising from tissue insulin resistance and gradually progressing to a state characterized by complete loss of secretory activity of the beta-cells of the pancreas. T2DM is a major contributor to the very large rise in the rate of non-communicable diseases affecting developed as well as developing nations. In this mini-review, we endeavor to outline the current management principles, including the spectrum of medications that are currently used for pharmacologic management, for lowering the elevated blood glucose in T2DM.